INTRODUCTION
REASONS FOR DOING THE STUDY
The objective of this study is to provide an in-depth analysis and forecast of the global autoimmune products market. The focus is on products and therapies currently used or under development for treatment of a variety of autoimmune diseases.
The global market for autoimmune therapeutics was estimated at more than $34 billion in 2010, with mid-single-digit growth through 2016. Different segments such as arthritis and psoriasis treatments are projected to grow at a faster rate than other treatments.
The report will analyze the global markets by region and by disease, and then provide growth projections for each region and/or disease.
STUDY GOALS AND OBJECTIVES
Autoimmune diseases arise from an overactive immune response by the body against substances and tissues normally present in the body. An autoimmune reaction can be triggered by a foreign substance entering the body; an alteration of normal body substances through a virus, drug, sunlight, or radiation; a malfunctioning of cells that control antibody production within the body; and genetic predisposition.
Autoimmune diseases afflict individuals with symptoms presented in the neurological, musculoskeletal, dermatological, and gastrointestinal areas of the body. Women are more likely to have autoimmune disorders than men, and research is ongoing to determine why these diseases target women of all ages.
This report is designed to investigate the autoimmune market by disease and by treatment, with supporting tables and figures to illustrate projected growth. The report will include the U.S., Europe, Japan, and other countries such as China and India.
SCOPE OF REPORT
This report offers forecasts by product segment, disease, and geographical region from 2011 through 2016, including supporting analyses for projections.
This report is a valuable tool for anyone assessing the autoimmune market and attempting to devise a strategy for successful competition within it. It provides a thorough background on the structure of the autoimmune market and the chief challenges and opportunities it faces. It offers the information necessary for understanding the current market and for addressing the emerging one.
INTENDED AUDIENCE
This is an invaluable tool for business planners, acquisition specialists, licensing strategists, product managers, market research analysts, investing consultants, and others interested in the autoimmune market, its products, its participants, and its future.
METHODOLOGIES AND INFORMATION SOURCES
Information for this report has been obtained from a variety of primary and secondary research sources, including industry analysts, annual reports, SEC reports, the American Autoimmune Related Diseases Association (AARDA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMSD), the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID), the text Immunology (Lippincott Williams and Wilkins), government agencies outside the U.S., and journal articles. Secondary sources included literature searches, product literature, and press releases.
When precise information was unavailable, a consensus was made using reasonable assumptions and estimates based on historical data.
ANALYST CREDENTIALS
Peggy S. Lehr is the BCC Research Analyst of this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder and an MS in Communication from the University of Denver. Ms. Lehr has completed more than 13 reports for BCC, primarily on the medical and pharmaceutical industries. She has worked within the publishing industry for both for-profit and not-for-profit organizations.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at
www.bccresearch.com, enables readers to:
DISCLAIMER
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
